Healthcare >> Analyst Interviews >> March 15, 2019

The First Half of 2019 Expected to Be Rough for the Biotech Sector

Singh, Hartaj
Hartaj Singh is Managing Director and Senior Analyst, Biotechnology at Oppenheimer & Co. Inc. Prior to joining Oppenheimer, Mr. Singh was Managing Director and Senior Biotechnology Analyst at BTIG Securities. He began his sellside career at Lehman Brothers and subsequently moved to the buy side covering biotechnology at Visium Asset Management and Tecumseh Partners. He began his career as a clinical trial project manager for ClinTrials Research and also worked as a strategic analysis manager for Johnson & Johnson, both of which give him critical experience in clinical trial design. Mr. Singh has a B.A. in biology from Case Western Reserve University and also did extensive graduate work in computational neurobiology. He also holds an MBA from Duke University’s Fuqua School of Business. Profile
Word count: 3,717

TWST: What is your coverage universe today, and what is your outlook for it over the rest of 2019?

Mr. Singh: I cover a range of companies all